| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTRC |
| Uniprot No | Q99895 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-268aa |
| 氨基酸序列 | VVGGEDARPHSWPWQISLQYLKNDTWRHTCGGTLIASNFVLTAAHCISNTRTYRVAVGKNNLEVEDEEGSLFVGVDTIHVHKRWNALLLRNDIALIKLAEHVELSDTIQVACLPEKDSLLPKDYPCYVTGWGRLWTNGPIADKLQQGLQPVVDHATCSRIDWWGFRVKKTMVCAGGDGVISACNGDSGGPLNCQLENGSWEVFGIVSFGSRRGCNTRKKPVVYTRVSAYIDWINEKMQL |
| 预测分子量 | 28.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CTRC(胰凝乳蛋白酶C)重组蛋白研究的模拟参考文献示例(仅供参考，实际文献需通过学术数据库查询)：
---
1. **文献名称**: *"Functional Characterization of Recombinant CTRC Mutants in Chronic Pancreatitis"*
**作者**: Wang, X., et al.
**摘要**: 本研究通过在大肠杆菌中表达重组CTRC蛋白，分析了慢性胰腺炎患者中发现的CTRC突变体(如R116C和K247R)的酶活性和稳定性。结果显示，突变导致蛋白自降解加速，揭示了CTRC功能缺陷与胰腺炎发病机制的关联。
2. **文献名称**: *"High-Yield Production of Human CTRC in Pichia pastoris for Biochemical Studies"*
**作者**: Zhang, Y., et al.
**摘要**: 报道了一种在毕赤酵母系统中高效表达重组人源CTRC的方法，优化了发酵条件及纯化步骤，获得高纯度活性蛋白。该重组蛋白成功用于底物特异性及抑制剂筛选实验，为药物开发提供工具。
3. **文献名称**: *"CTRC-Mediated Activation of Trypsinogen: Insights from Recombinant Protein Assays"*
**作者**: Nemeth, B.C., et al.
**摘要**: 利用重组CTRC蛋白研究其对胰蛋白酶原的激活调控机制，发现CTRC通过选择性降解特定胰蛋白酶原异构体来防止胰腺内过早激活，为理解胰腺自消化保护机制提供实验依据。
---
**提示**：以上为示例性内容，实际文献请通过 **PubMed**、**Web of Science** 或 **Google Scholar** 以关键词“CTRC recombinant protein”、“Chymotrypsin C expression”检索最新研究。
**Background of CTRC Recombinant Protein**
Chymotrypsin C (CTRC), a serine protease primarily synthesized in the pancreas, plays a critical role in regulating digestive enzyme activation and homeostasis. It specifically cleaves and inactivates trypsinogen, preventing premature trypsin activation—a key mechanism to protect against pancreatitis. Mutations in the *CTRC* gene are linked to hereditary and chronic pancreatitis, highlighting its clinical relevance.
Recombinant CTRC protein is produced via genetic engineering, where the *CTRC* gene is cloned into expression systems (e.g., *E. coli*, mammalian cells) to generate purified, functional protein. This approach ensures consistent quality and scalability, bypassing challenges in isolating CTRC from natural sources. The recombinant form retains enzymatic activity, enabling studies on its structure-function relationships, interaction with substrates/inhibitors, and pathogenic mutations.
Research applications include elucidating CTRC's role in pancreatic disease mechanisms, screening therapeutic agents to modulate its activity, and developing diagnostic tools. Additionally, recombinant CTRC serves as a control in biochemical assays or as an antigen for antibody production. Its engineered variants (e.g., tagged, mutated) further facilitate purification and tracking in experimental settings.
Overall, CTRC recombinant protein is a vital tool for advancing understanding of pancreatic physiology, disease pathways, and therapeutic innovation.
×
